Chiesi Marks Significant Step in its Net Zero Journey with MHRA Approval of its First Pressurized Metered-Dose Inhalers Containing a Next-Generation, Low GWP Propellant
Category:Innovation
Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products. Chiesi’s propellant transition is expected to cut the carbon footprint of their beclometasone products by up to 90% versus the current propellant and aims to ensure continuity of care for patients by preserving device choice while addressing the environmental impact of these pMDIs.
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
